Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors at 2 institutions in 1 country.
Gustavo Garcia *Department of Molecular and Medical Pharmacology, University of California, Los Angelesgrid.19006.3e, Los Angeles, California, USA.ORCID 0000-0002-1649-9251
Nikhil Chakravarty *Department of Epidemiology, University of California, Los Angelesgrid.19006.3e, Los Angeles, California, USA.ORCID 0000-0002-4603-1713
Angel Elma AbuDepartment of Chemistry and Biochemistry, University of California, Los Angelesgrid.19006.3e, Los Angeles, California, USA.
Arjit Vijey JeyachandranDepartment of Molecular and Medical Pharmacology, University of California, Los Angelesgrid.19006.3e, Los Angeles, California, USA.
Kari-Ann TakanoDivision of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angelesgrid.19006.3e, Los Angeles, California, USA.
Rebecca BrownDepartments of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angelesgrid.19006.3e, California, USA.
Kouki MorizonoDivision of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angelesgrid.19006.3e, Los Angeles, California, USA.
Vaithilingaraja Arumugaswami *Department of Molecular and Medical Pharmacology, University of California, Los Angelesgrid.19006.3e, Los Angeles, California, USA.ORCID 0000-0002-6872-5118
University of California, Los Angeles · USCalifornia NanoSystems Institute · US
Funding
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Robert Damoiseaux · 1985 to 2026
$134.5M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZACK, JEROME A. · 1991 to 2018
$39.9M
Viral Immunology CoreU19AI149504 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHEN, IRVIN S.Y., KITCHEN, SCOTT G · 2020 to 2024
$14.3M
Metabolic and epigenetic reprogramming of vital organs in SARS-CoV-2 induced systemic toxicityR01DK132735 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARUMUGASWAMI, VAITHILINGARAJA, DEB, ARJUN · 2021 to 2023
$6.0M
Interplay between AMPK and Hippo Signaling Regulates Ocular Antiviral Response to Zika virus infectionR01EY032149 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Vaithilingaraja Arumugaswami, Ashok Kumar · 2021 to 2026
$2.8M
Developing three-dimensional antisense oligonucleotide drugs against COVID-19R01AI163216 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GUO, FENG · 2021 to 2025
$2.3M
B-cell-specific transduction for anti-HIV antibody and B-cell receptor expressionR01AI145044 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORIZONO, KOKI · 2019 to 2023
Zika virus (ZIKV), a mosquito-borne human pathogen, causes dire congenital brain developmental abnormalities in children of infected mothers. The global health crisis precipitated by this virus has led to a concerted effort to develop effective therapies and prophylactic measures although, unfortunately, not very successfully. The error-prone nature of RNA viral genome replication tends to promote evolution of novel viral strains, which could cause epidemics and pandemics. As such, our objective was to develop a safe and effective replication-deficient ZIKV vector-based vaccine candidate. We approached this by generating a ZIKV vector containing only the nonstructural (NS) 5'-untranslated (UTR)-NS-3' UTR sequences, with the structural proteins capsid (C), precursor membrane (prM), and envelope (E) (CprME) used as a packaging system. We efficiently packaged replication-deficient Zika vaccine particles in human producer cells and verified antigen expression
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Replication-Deficient Zika Vector-Based Vaccine Provides Maternal and Fetal Protection in Mouse Model. · full record | OpenQuestion